TRIAL DETAIL

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Drug:
Trial Name:
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Recruiting
Phase:
1
Start Date 10/01/2013
Age of Trial (yrs) 6
Treatment Phase:
Gleevec-resistant
Drug Category:
PD-1 + LAG-3 Inhibitor
Strategy:
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CA224-020
Sponsor:
Bristol-Myers Squibb
Patient Contact:
Clinical.Trials@bms.com First line of the email MUST contain NCT# and Site #.
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
Inclusion Criteria:

Part A, Dose Escalation: Advanced (metastatic and/or unresectable) and incurable solid tumors, naive to Immune Cell Modulating Antibody Regimens (ICMARs)
Part B, Dose Escalation: Advanced (metastatic and/or unresectable) and incurable solid tumors,

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
5841 S. Maryland Ave
Chicago
IL
60637
USA
Baltimore
MD
21231
USA
450 Brookline Ave
Boston
MA
02215-5450
USA
1275 York Ave
New York
NY
10065
USA
Portland
OR
97213
USA
4100 John R
Detroit
MI
48201
USA
Helsinki
FIN-00029
Finland
Toulouse
31052
France
Napoli
80131
Italy
119-129
Barcelona
08035
Spain
Plamplona
Spain
Lausanne
CH-1011
Switzerland
Seattle
WA
98109
USA
Vienna
1090
Austria